NCT01308762: A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients |
|
|
| Completed | 1 | 19 | Europe | Heat killed whole cell M. obuense (IMM-101) 0.1 mg, IMM-101, Mycobaterium obuense, Heat-killed whole cell M.obuense (IMM-101) 0.5 mg, Heat killed whole cell M.obuense (IMM-101) 1.0 mg | Immodulon Therapeutics Ltd, HCA International Limited, Theradex | Melanoma | 09/10 | 09/10 | | |
